Angiotensin II receptor blocker and statin combination therapy associated with higher skeletal muscle index in patients with cardiovascular disease: A retrospective study

Harada, Haruhito; Nishiyama, Yasuhiro; Niiyama, Hiroshi; Katoh, Atsushi; Kai, Hisashi

doi:10.1111/jcpt.13540

Cited by 4 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies reported significantly lower muscle quality in statin users than in those who stopped statin therapy 12 . However, other studies showed that statins effectively reduced some degree of muscle mass atrophy and prevented sarcopenia development 17,18,38 . In the present study, patients administered statins showed higher muscle mass at admission and discharge than those who were not.…”

Section: Discussioncontrasting

confidence: 51%

“…12 However, other studies showed that statins effectively reduced some degree of muscle mass atrophy and prevented sarcopenia development. 17,18,38 In the present study, patients administered statins showed higher muscle mass at admission and discharge than those who were not. Nevertheless, the limited duration of the observational period, which spanned only a few months, might have precluded the identification of changes in skeletal muscle mass.…”

Section: Discussionsupporting

confidence: 50%

See 1 more Smart Citation

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Matsumoto¹,

Yoshimura²,

Nagano³

et al. 2023

Geriatrics Gerontology Int

View full text Add to dashboard Cite

AimThe effects of statins on muscle health are not well established. Therefore, this study investigated the impact of statin use on muscle strength and mass recovery in patients with sarcopenia after stroke.MethodsThis retrospective cohort study included stroke patients with sarcopenia hospitalized between 2015 and 2021 at a post‐acute rehabilitation hospital. Sarcopenia was diagnosed using handgrip strength and skeletal muscle mass index measured using bioelectrical impedance analysis according to the 2019 criteria of the Asian Working Group for Sarcopenia. The study outcomes included handgrip strength and skeletal muscle mass index at hospital discharge. We used multivariate analyses to examine whether statin use was independently associated with the outcomes. Statistical significance was set at P < 0.05.ResultsOf the 586 patients enrolled, 241 (mean age 79.3 years, 44.4% men) presented with sarcopenia and were included in the analysis. Statin use was observed in 61 (25.3%) patients. Statin use was independently negatively associated with handgrip strength at discharge (β = −0.095, P = 0.032), but not with skeletal muscle mass index at discharge (β = 0.019, P = 0.692).ConclusionsStatin use was negatively associated with muscle strength recovery, but not with muscle mass in patients with sarcopenia who underwent rehabilitation after stroke. To maximize outcomes, sufficient consideration is needed for statin use in these patients. Geriatr Gerontol Int 2023; ••: ••–••.

show abstract

Section: Discussioncontrasting

confidence: 51%

Section: Discussionsupporting

confidence: 50%

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Matsumoto¹,

Yoshimura²,

Nagano³

et al. 2023

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

“…Recently, an observational study linked the combination of ARBs and statin with higher ALM in patients with cardiovascular disease ( 38 ), however, research around the impact of statins on skeletal muscle is controversial. Mechanistic studies conducted in rats have shown that statins could induce acute muscle damage ( 39 ), although in mdx mice with Duchenne muscular dystrophy, no signs of inflammation, fibrosis, and angiogenesis reflecting muscle injury were observed ( 40 ).…”

Section: Discussionmentioning

confidence: 99%

Is sarcopenia an associated factor of increased administration of specific medications in patients with heart failure? A systematic review and meta-analysis

Saied,

Prokopidis,

Adenaya

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundThere is controversy in relation to commonly used drugs in heart failure (HF) and their impact on muscle function. The aim of this study was to evaluate the odds of receiving specific medications often used in clinical practice by patients with HF and sarcopenia vs. without sarcopenia.MethodsA systematic literature search of cohort studies via databases (PubMed, Web of Science, Scopus, and Cochrane Library) was conducted from inception until March 2023. To determine if sarcopenia is linked to a higher number of specific HF-related medications, a meta-analysis using a random-effects model was used to calculate the pooled effects.ResultsOur main analyses showed no significant association of sarcopenia with administration of higher HF-related medication count vs. those without sarcopenia. Those with lower appendicular lean mass (ALM) had significantly lower odds of receiving angiotensin converting enzyme inhibitors (ACE-Is)/angiotensin receptor blockers (ARBs) (OR: 0.68, 95%CI 0.50–0.90, I2 = 12%, P < 0.01) vs. patients with higher ALM for which age could be an important confounder based on meta-regression. No statistically significant differences were found in relation to B-blockers OR: 0.84, 95%CI 0.63–1.12, I2 = 7%, P = 0.24) and loop diuretics (OR: 1.19, 95%CI 0.87–1.63, I2 = 0%, P = 0.27). Regarding handgrip strength, gait speed, and short physical performance battery, our narrative synthesis found mixed results.ConclusionThis systematic review and meta-analysis did not find a relationship of specific medication count in sarcopenia vs. without sarcopenia in patients with HF, although increased odds of ACE-I/ARB was shown in those with higher ALM.Systematic Review RegistrationPROSPERO (CRD42023411137).

show abstract

“…[107,108] Statins can increase SMI in patients with heart disease. [109,110] A study has shown that in older individuals undergoing progressive resistance training, combination therapy with metformin and statins can increase muscle fiber area, but has no significant effect on strength. [111] The effect of statins on sarcopenia in patients with T2DM needs further research.…”

Section: Intervention Measuresmentioning

confidence: 99%

A review on associated factors and management measures for sarcopenia in type 2 diabetes mellitus

Zhang,

Huang

et al. 2024

Medicine

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, insulin resistance, and insufficient insulin secretion. Sarcopenia, as a new complication of diabetes, is characterized by the loss of muscle mass and the progressive decline of muscle strength and function in T2DM patients, which has a serious impact on the physical and mental health of patients. Insulin resistance, mitochondrial dysfunction, and chronic inflammation are common mechanisms of diabetes and sarcopenia. Reasonable exercise training, nutrition supplement, and drug intervention may improve the quality of life of patients with diabetes combined with sarcopenia. This article reviews the relevant factors and management measures of sarcopenia in T2DM patients, in order to achieve early detection, diagnosis, and intervention.

show abstract

Angiotensin II receptor blocker and statin combination therapy associated with higher skeletal muscle index in patients with cardiovascular disease: A retrospective study

Cited by 4 publications

References 38 publications

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Is sarcopenia an associated factor of increased administration of specific medications in patients with heart failure? A systematic review and meta-analysis

A review on associated factors and management measures for sarcopenia in type 2 diabetes mellitus

Contact Info

Product

Resources

About